PharmaTher Holdings Ltd. (PHRRF)
USD 0.16
(-0.62%)
USD 0.16
(-0.62%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -2.13 Million CAD | 63.96% |
| 2023 | -5.91 Million CAD | 35.34% |
| 2022 | -9.15 Million CAD | -229.54% |
| 2021 | -2.77 Million CAD | -615.3% |
| 2020 | -388.38 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -2.42 Million CAD | 22.94% |
| 2024 Q2 | -3.15 Million CAD | 26.1% |
| 2024 Q1 | -4.26 Million CAD | 27.95% |
| 2024 Q4 | -2.13 Million CAD | 12.18% |
| 2023 Q2 | -7.14 Million CAD | 7.75% |
| 2023 Q3 | -6.63 Million CAD | 7.17% |
| 2023 Q4 | -5.91 Million CAD | 10.77% |
| 2023 Q1 | -7.74 Million CAD | 15.38% |
| 2023 FY | -5.91 Million CAD | 35.34% |
| 2022 Q4 | -9.15 Million CAD | 9.94% |
| 2022 Q3 | -10.16 Million CAD | 9.85% |
| 2022 Q2 | -11.27 Million CAD | -363.52% |
| 2022 Q1 | -2.43 Million CAD | 12.43% |
| 2022 FY | -9.15 Million CAD | -229.54% |
| 2021 Q1 | -1.57 Million CAD | 0.0% |
| 2021 FY | -2.77 Million CAD | -615.3% |
| 2021 Q3 | -3.63 Million CAD | -264.95% |
| 2021 Q4 | -2.77 Million CAD | 23.67% |
| 2021 Q2 | -997.23 Thousand CAD | 36.8% |
| 2020 FY | -388.38 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 113.533% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 151.802% |
| SQZ Biotechnologies Company | -36.23 Million USD | 94.113% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 104.985% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 66.163% |
| Mesoblast Limited | 55.85 Million USD | 103.819% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 330.076% |
| Genus plc | 190.6 Million USD | 101.119% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 195.411% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 275.735% |
| Marizyme, Inc. | 18.56 Million USD | 111.488% |
| ContraFect Corporation | -6.02 Million USD | 64.6% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 413.71% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1684.408% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 284.627% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 195.139% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 138.773% |
| MultiCell Technologies, Inc. | 90.04 USD | 2369303.687% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -190.64% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 116.478% |
| EV Biologics, Inc. | 1.36 Million USD | 255.941% |
| Q BioMed Inc. | 4.06 Million USD | 152.543% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 106.982% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 442.763% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 311.69% |
| Biomind Labs Inc. | 711.4 Thousand USD | 399.863% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 101.943% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 116.657% |
| Skye Bioscience, Inc. | -5.72 Million USD | 62.715% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 347.981% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1625.873% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 137.767% |
| IMV Inc. | 7.67 Million USD | 127.811% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 10837.56% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 196.878% |
| GB Sciences, Inc. | 1.74 Million USD | 222.086% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1060.702% |
| HST Global, Inc. | 96.79 Thousand USD | 2303.91% |
| CSL Limited | 10.52 Billion USD | 100.02% |
| Halberd Corporation | 144.72 Thousand USD | 1574.03% |
| Enzolytics Inc. | 981.65 Thousand USD | 317.309% |
| Resverlogix Corp. | 6.45 Million USD | 133.068% |
| Affymax, Inc. | -5.59 Million USD | 61.886% |
| SYBLEU INC | 473.71 Thousand USD | 550.32% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -216.931% |
| argenx SE | -2.02 Billion USD | 99.895% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 104.911% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 95.462% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 178.757% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 75.868% |
| AVAX Technologies, Inc. | -5.9 Million USD | 63.863% |
| Zenith Capital Corp. | 10.06 Thousand USD | 21296.651% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.799% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 1164.317% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 189.405% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1396.726% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 103.523% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 206.694% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | 16.996% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 693.042% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 110.521% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -11545.545% |
| BioStem Technologies, Inc. | 4.47 Million USD | 147.702% |
| ONE Bio Corp. | 9.04 Million USD | 123.598% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 1159.969% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -162742.061% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 1134.459% |
| Agentix Corp. | 37.63 Thousand USD | 5768.813% |
| LadRx Corporation | -2.03 Million USD | -4.751% |
| Cell Source, Inc. | 9.23 Million USD | 123.107% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -10352.916% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 435.854% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 435.854% |
| NovAccess Global Inc. | 2.17 Million USD | 197.924% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 130.169% |
| Itoco Inc. | 228.3 Thousand USD | 1034.378% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1668.679% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 143.035% |
| Kadimastem Ltd | -253.1 Thousand USD | -742.835% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 630.854% |
| CytoDyn Inc. | 20.26 Million USD | 110.528% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -329611.128% |
| Mobile Lads Corp. | 484.23 Thousand USD | 540.539% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -22916.322% |
| Qrons Inc. | 351.42 Thousand USD | 707.02% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 127.683% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -754.591% |
| Rebus Holdings, Inc. | 305 Thousand USD | 799.42% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 147.862% |
| International Stem Cell Corporation | 2.59 Million USD | 182.364% |
| Bioxytran, Inc. | 1.89 Million USD | 212.34% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 3517.927% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 197.814% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 162.121% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 124.941% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 376.108% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -70.658% |
| Neutra Corp. | 52.18 Thousand USD | 4187.667% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 14.294% |
| PureTech Health plc | -167.19 Million USD | 98.724% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -771.034% |
| IXICO plc | -4.44 Million USD | 52.004% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 116.138% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 103.889% |
| CSL Limited | 10.52 Billion USD | 100.02% |
| Cellectis S.A. | -43.81 Million USD | 95.132% |